Key result
Higher serum Pcsk9 levels were positively associated with the severity of coronary artery lesions (r = 0.173) and an increased risk of major adverse cardiac events (HR 1.01 per ng/mL increase) in young men with premature myocardial infarction.
Why the study?
It was unclear whether Pcsk9 contributed to coronary artery lesion severity in patients with premature myocardial infarction.
Cohort (n=332)
No
Hazard Ratio: 1.01 (95% CI 1–1.01)
p-value: p=<0.001
In young men with premature myocardial infarction, higher serum Pcsk9 levels correlate with more severe coronary artery lesions and an increased risk of subsequent major adverse cardiac events.
Supports Pcsk9 as prognostic biomarker in premature MI; leaves open whether inhibition improves outcomes.
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (Pcsk9) correlated with incidence and prognosis of coronary heart disease. However, it is unclear whether Pcsk9 contributed to coronary artery lesion severity in patients with premature myocardial infarction (PMI). The present study investigated associations between Pcsk9 and coronary artery lesion severity in PMI patients who underwent coronary angiography (CAG). METHODS: This prospective cohort study included young men (age ≤ 45 years, n = 332) with acute MI who underwent CAG between January 2017 and July 2019. Serum Pcsk9 levels and clinical characteristics were evaluated. SYNTAX scores (SYNergy between percutaneous coronary intervention with [paclitaxel-eluting] TAXUS stent and cardiac surgery) were calculated to quantify coronary artery lesions. RESULTS: Serum Pcsk9 levels were positively associated with SYNTAX scores (r = 0.173, P < 0.05). The diagnostic cutoff value of PSCK9 level was 122.9 ng/mL, yielding an area under the curve (AUC) of 0.63, sensitivity 81%, and specificity 40%. Serum Pcsk9, LDL-C, Apob, NT-proBnp, CK level, and diabetes history were independent predictors of high SYNTAX scores (P < 0.05). After stratifying by serum LDL-C level (cutoff = 2.6 mmol/L), medium-high Pcsk9 levels had increased risk of high SYNTAX scores in patients with high LDL-C (P < 0.05), and higher serum Pcsk9 levels had increased risk of major adverse cardiac events (MACE) after adjusting for confounding factors (P < 0.05). CONCLUSION: Serum Pcsk9 levels correlates with severity of coronary artery lesion in PMI patients and may serve as a biomarker for severity of coronary artery stenosis in this patient population, which may contribute to risk stratification.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2021) conducted a cohort in Premature myocardial infarction (n=332). Serum Pcsk9 levels vs. Low serum Pcsk9 levels was evaluated on Major adverse cardiac events (MACE) (HR 1.01, 95% CI 1.00-1.01, p=<0.001). Higher serum Pcsk9 levels were positively associated with the severity of coronary artery lesions (r = 0.173) and an increased risk of major adverse cardiac events (HR 1.01 per ng/mL increase) in young men with premature myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: